2020年11月17日 · Therefore, this study suggests the GSK-LSD1 as a therapeutic agent for severe COVID-19 patients that are difficult to treat by directly targeting NF-κB. COVID-19 …

phosphorylates LSD1, and GSK-LSD1, which directly inhibits activation of LSD1, could improve survival rate in the septic mouse model by inhibiting the PKCα-LSD1-NF-κB pathway. 3 In this

GSK-LSD1 dihydrochloride is a potent, selective and irreversible lysine specific demethylase 1 (LSD1) inhibitor with an IC50 of 16 nM. GSK-LSD1 shows more than 1000 fold selectivity over …

2022年10月15日 · GSK-LSD1 2HCl is an irreversible and selective LSD1 inhibitor. Pre-treatment with LSD1 inhibitor alleviated LPS/D-Gal-induced liver damage, decreased serum levels of …

Gsk-lsd1 | C14H20N2 | CID 71522234 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity …

Lysine specific demethylase 1 (LSD1) is a histone demethylase found in various transcriptional co-repressor complexes. LSD1 is involved in ES cell differentiation, hematopoiesis, and has …

2020年11月17日 · GSK-LSD1, an LSD1 inhibitor, quashes SARS-CoV-2-triggered cytokine release syndrome in-vitro Signal Transduct Target Ther . 2020 Nov 17;5(1):267. doi: …

GSK-LSD1 is an irreversible, mechanism-based inhibitor of LSD1 (IC 50 = 16 nM) that is >1,000-fold selective over the closely related FAD-utilizing enzymes LSD2, MAO-A, and MAO-B. 1 …

GSK-LSD1 is a potent and selective inhibitor of lysine specific demethylase 1 (LSD1). GSK-LSD1 potently inhibits proliferation of varies cancer cell lines by changing gene expression patterns. …

2020年11月17日 · GSK-LSD1 inhibits NF-κB p65-mediated cytokine storm in PBMCs isolated from severe COVID-19 patients.